# A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

> **NCT02933762** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-54175446
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02933762
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02933762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02933762, "A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02933762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*